[1]苗岳松,刘 杰,刘 昕,等.循环肿瘤细胞在膀胱癌诊疗中的应用价值[J].医学信息,2021,34(08):72-75.[doi:10.3969/j.issn.1006-1959.2021.08.019]
　MIAO Yue-song,LIU Jie,LIU Xin,et al.The Application Value of Circulating Tumor Cells in the Diagnosis and Treatment of Bladder Cancer[J].Medical Information,2021,34(08):72-75.[doi:10.3969/j.issn.1006-1959.2021.08.019]
点击复制

循环肿瘤细胞在膀胱癌诊疗中的应用价值()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年08期
页码:
72-75
栏目:
论著
出版日期:
2021-04-15

文章信息/Info

Title:
The Application Value of Circulating Tumor Cells in the Diagnosis and Treatment of Bladder Cancer
文章编号:
1006-1959（2021）08-0072-04
作者:
苗岳松; 刘 杰; 刘 昕; 等
（承德医学院附属医院泌尿外科，河北 承德 067000）
Author(s):
MIAO Yue-song; LIU Jie; LIU Xin; et al.
(Department of Urology,Affiliated Hospital of Chengde Medical University,Chengde 067000,Hebei,China)
关键词:
循环肿瘤细胞; 膀胱癌; 肿瘤标志物; 免疫磁珠阴性富集法
Keywords:
Circulating tumor cells; Bladder cancer; Tumor markers; Immunomagnetic bead negative enrichment method
分类号:
R737.14
DOI:
10.3969/j.issn.1006-1959.2021.08.019
文献标志码:
A
摘要:
目的 检测膀胱癌患者外周血中循环肿瘤细胞（CTCs）的表达情况，探究在膀胱癌手术前后动态监测CTCs的价值。方法 选择2018年10月~2019年6月就诊于承德医学院附属医院泌尿外科的92例膀胱癌患者作为试验组，另外选择同期22例健康志愿者作为对照组，采用免疫磁珠阴性富集法结合荧光细胞化学染色技术（SE-iFISH）检测两组外周血中CTCs水平，绘制受试者工作曲线（ROC），确定cut-off值，分析外周血中CTCs与试验组肿瘤浸润程度、病理分级、肿瘤分期及多样性的关系。结果 试验组CTCs阳性率高于对照组（91.30% vs 4.50%），差异有统计学意义（P＜0.05）；当cut-off值为1个/7.5 ml时，CTC诊断膀胱癌的敏感性和特异性分别为91.30%、95.50%；不同浸润程度、病理分级的膀胱癌患者CTCs阳性率比较，差异有统计学意义（P＜0.05）；不同年龄、性别、肿瘤分期、多样性的膀胱癌患者CTCs阳性率比较，差异无统计学意义（P＞0.05）。结论 CTCs可作为诊断膀胱癌的评价指标，具有潜在的临床应用价值，可作为监测膀胱癌治疗疗效的肿瘤标志物，且其表达与肿瘤的浸润程度、病理分级有一定关系。
Abstract:
Objective To detect the expression of circulating tumor cells (CTCs) in the peripheral blood of patients with bladder cancer, and to explore the value of dynamic monitoring of CTCs before and after bladder cancer surgery.Methods 92 patients with bladder cancer who were admitted to the Department of Urology, Affiliated Hospital of Chengde Medical University from October 2018 to June 2019 were selected as the experimental group.In addition, 22 healthy volunteers during the same period were selected as the control group, and the CTCs levels in the peripheral blood of the two groups were detected by the immunomagnetic bead negative enrichment method combined with the fluorescent cytochemical staining technique (SE-iFISH).Draw receiver operating curve (ROC), determine cut-off value, and analyze the relationship between CTCs in peripheral blood and tumor infiltration degree, pathological grade, tumor stage and diversity of the experimental group.Results The positive rate of CTCs in the experimental group was higher than that in the control group (91.30% vs 4.50%),the difference was statistically significant (P＜0.05);When the cut-off value was 1/7.5 ml, the sensitivity and specificity of CTC in diagnosing bladder cancer were 91.30% and 95.50%, respectively; comparison of the positive rates of CTCs in bladder cancer patients with different infiltration degrees and pathological grades,the difference was statistically significant (P＜0.05);There was no significant difference in the positive rate of CTCs among bladder cancer patients of different ages, genders, tumor stages, and diversity (P>0.05).Conclusion CTCs can be used as an evaluation index for the diagnosis of bladder cancer and have potential clinical application value. They can be used as tumor markers to monitor the therapeutic effect of bladder cancer, and their expression has a certain relationship with the degree of tumor invasion and pathological grade.

参考文献/References:

[1]Torre LA,Bray F,Siegel RL,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108. [2]贺宇彤,李道娟,梁迪,等.2014年中国膀胱癌发病和死亡分析[J].中华肿瘤杂志,2018,40(9):647-652. [3]De Velasco G,Wankowicz SA,Madison R,et al.Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma[J].Br J Cancer,2018,118(9):1238-1242. [4]Dhar M,Pao E,Renier C,et al.Label-free enumeration, collection and downstream cytological and cytogenetic analysis of circulating tumor cells[J].Sci Rep,2016(6):35474. [5]Kulemann B,Rosch S,Seifert S,et al.Pancreatic cancer:Circulating Tumor Cells and Primary Tumors show Heterogeneous KRAS Mutations[J].Sci Rep,2017,7(1):4510. [6]Whitworth J,Smith PS,Martin JE,et al.Comprehensive Cancer-Predisposition Gene Testing in an Adult Multiple Primary Tumor Series Shows a Broad Range of Deleterious Variants and Atypical Tumor Phenotypes[J].Am J Hum Genet,2018,103(1):3-18. [7]Langlands F,Cornford E,Rakha E,et al.Imaging overview of metaplastic carcinomas of the breast:a large study of 71 cases[J].Br J Radiol,2016,89(1064):20140644. [8]Hashimoto M,Tanaka F,Yoneda K,et al.The clinical value of circulating tumour cells (CTCs)in patients undergoing pulmonary metastasectomy for metastatic colorectal cancer[J].J Thorac Dis,2018,10(3):1569-1577. [9]Li Z,Zhang X,Jiang X,et al.Outcome of surgical resection for brain metastases and radical treatment of the primary tumor in Chinese non-small-cell lung cancer patients[J].Onco Targets Ther,2015(8):855-860. [10]Wang XX,Levi J,Luo Y,et al.SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy:Sglt2 Protein Inhibition Decreases Renal Lipid Accumulation,Inflammation,And The Development Of Nephropathy In Diabetic Mice[J].J Biol Chem,2017,292(13):5335-5348. [11]Giuliano M,Shaikh A,Lo HC,et al.Perspective on Circulating Tumor Cell Clusters:Why It Takes a Village to Metastasize[J].Cancer Res,2018,78(4):845-852. [12]Bergmann S,Coym A,Ott L,et al.Evaluation of PD-L1 expression on circulating tumor cells(CTCs)in patients with advanced urothelial carcinoma(UC)[J].Oncoimmunology,2020,9(1):1738798. [13]Chou R,Gore JL,Buckley D,et al.Urinary Biomarkers for Diagnosis of Bladder Cancer:A Systematic Review and Meta-analysis[J].Ann Intern Med,2015,163(12):922-931. [14]Micalizzi DS,Maheswaran S,Haber DA.A conduit to metastasis: circulating tumor cell biology[J].Genes Dev,2017,31(18):1827-1840. [15]Thalgott M,Rack B,Horn T,et al.Detection of Circulating Tumor Cells in Locally Advanced High-risk Prostate Cancer During Neoadjuvant Chemotherapy and Radical Prostatectomy[J].Anticancer Res,2015,35(10):5679-5685. [16]Bork U,Rahbari NN,Scholch S,et al.Circulating tumour cells and outcome in non-metastatic colorectal cancer:a prospective study[J].Br J Cancer,2015,112(8):1306-1313. [17]Sotelo MJ,Sastre J,Maestro ML,et al.Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer[J].Ann Oncol,2015,26(3):535-541. [18]Zhang J,Shi H,Jiang T,et al.Circulating tumor cells with karyotyping as a novel biomarker for diagnosis and treatment of nasopharyngeal carcinoma[J].BMC Cancer,2018,18(1):1133. [19]张浩强,李明辉,王臻,等.免疫荧光联合原位杂交技术检测骨肉瘤患者外周血中循环肿瘤细胞的表达及临床意义[J].中华肿瘤杂志,2017,39(7):485-489. [20]许扬梅,刘巧珍,刘沁颖,等.流式细胞术检测结直肠癌根治术前后循环肿瘤细胞和循环肿瘤干细胞及其临床预测价值[J].中国肿瘤生物治疗杂志,2017,24(4):355-361.

相似文献/References:

[1]刘 坤,陈德春.基于生信学方法分析GSDM基因家族在膀胱癌的表达及临床意义[J].医学信息,2022,35(10):14.[doi:10.3969/j.issn.1006-1959.2022.10.003]
　LIU Kun,CHEN De-chun.Expression and Clinical Significance of GSDM Gene Family in Bladder Cancer Based on Bioinformatics Analysis[J].Medical Information,2022,35(08):14.[doi:10.3969/j.issn.1006-1959.2022.10.003]
[2]幸世玉.经尿道电切术联合吉西他滨灌注治疗膀胱癌的临床效果分析[J].医学信息,2018,31(20):91.[doi:10.3969/j.issn.1006-1959.2018.20.026]
　XING Shi-yu.Clinical Analysis of Transurethral Resection Combined with Gemcitabine Perfusion in the Treatment of Bladder Cancer[J].Medical Information,2018,31(08):91.[doi:10.3969/j.issn.1006-1959.2018.20.026]
[3]熊波波,张劲松,王海峰,等.miRNAs与泌尿系肿瘤关系的研究进展[J].医学信息,2019,32(05):35.[doi:10.3969/j.issn.1006-1959.2019.04.013]
　XIONG Bo-bo,ZHANG Jin-song,WANG Hai-feng,et al.Research Progress on the Relationship between miRNAs and Urinary Tumors[J].Medical Information,2019,32(08):35.[doi:10.3969/j.issn.1006-1959.2019.04.013]
[4]王 猛.循环肿瘤细胞在肺癌诊疗中的临床研究进展[J].医学信息,2019,32(15):58.[doi:10.3969/j.issn.1006-1959.2019.15.019]
　WANG Meng.Progress in Clinical Research of Circulating Tumor Cells in the Diagnosis and Treatment of Lung Cancer[J].Medical Information,2019,32(08):58.[doi:10.3969/j.issn.1006-1959.2019.15.019]
[5]郝保良.等离子针状电极剜切治疗非肌层浸润性膀胱癌的效果[J].医学信息,2021,34(04):148.[doi:10.3969/j.issn.1006-1959.2021.04.040]
　HAO Bao-liang.Effect Plasma Needle Electrode Enucleation for Non-muscular Invasive Carcinoma of Urinary Bladder[J].Medical Information,2021,34(08):148.[doi:10.3969/j.issn.1006-1959.2021.04.040]
[6]杜国望,陈 昊,苗岳松,等.保留膀胱综合疗法治疗肌层浸润性膀胱癌的效果[J].医学信息,2020,33(06):122.[doi:10.3969/j.issn.1006-1959.2020.06.038]
　DU Guo-wang,CHEN Hao,MIAO Yue-song,et al.Effect of Bladder-preserving Comprehensive Therapy on Muscular Invasive Bladder Cancer[J].Medical Information,2020,33(08):122.[doi:10.3969/j.issn.1006-1959.2020.06.038]
[7]张晓伟,陈 明,田谋利,等.术中体位变化和气腹对机器人辅助腹腔镜根治性膀胱切除患者眼压的影响[J].医学信息,2020,33(14):113.[doi:10.3969/j.issn.1006-1959.2020.14.034]
　ZHANG Xiao-wei,CHEN Ming,TIAN Mou-li,et al.Effects of Intraoperative Posture Changes and Pneumoperitoneum on Intraocular Pressure in Patients with Robot-assisted Laparoscopic Radical Cystectomy[J].Medical Information,2020,33(08):113.[doi:10.3969/j.issn.1006-1959.2020.14.034]
[8]熊 雄,熊 斌,姚 烽.CYFRA21-1与BTA stat检测在膀胱癌诊断中的应用价值[J].医学信息,2020,33(22):104.[doi:10.3969/j.issn.1006-1959.2020.22.029]
　XIONG Xiong,XIONG Bin,YAO Feng.Application Value of CYFRA21-1 and BTA Stat in the Diagnosis of Bladder Cancer[J].Medical Information,2020,33(08):104.[doi:10.3969/j.issn.1006-1959.2020.22.029]
[9]孙祖刚,王咸钟,谢习颂,等.慢性炎症分子基础及信号通路在膀胱癌中的作用[J].医学信息,2020,33(19):31.[doi:10.3969/j.issn.1006-1959.2020.19.010]
　SUN Zu-gang,WANG Xian-zhong,XIE Xi-song,et al.The Molecular Basis of Chronic Inflammation and the Role of Signal Pathways in Bladder Cancer[J].Medical Information,2020,33(08):31.[doi:10.3969/j.issn.1006-1959.2020.19.010]
[10]任默涵,于东海,吴 迪.MTHFD2基因在膀胱癌中的表达、功能富集及信号通路的生物信息学分析[J].医学信息,2022,35(24):18.[doi:10.3969/j.issn.1006-1959.2022.24.004]
　REN Mo-han,YU Dong-hai,WU Di.Expression, Functional Enrichment and Bioinformatics Analysis of MTHFD2 Gene in Bladder Cancer[J].Medical Information,2022,35(08):18.[doi:10.3969/j.issn.1006-1959.2022.24.004]

更新日期/Last Update: 1900-01-01